GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Inclusion Criteria: * Albuminuria defined as urinary albumin:creatinine ratio ≥ 25 mg/g (or protein:creatinine ratio ≥ 30 mg/g) or albuminuria \> 30 mg/24h * eGFR \> 25 and \< 75 ml/minute 1.73m2 * BMI between 19 kg/m2 and 30 kg/m2 * Treatment with an ACE inhibitor and/or ARB at the maximum tolerated (for the individual subject) dose. The maximum tolerated dose for an individual subject may be less than the maximum labeled dose or may be zero if the medical reason is documented. * Mean systolic and diastolic blood pressure (determined as the average of three replicates) must be \< 180/90mmHg * Pre-menopausal women of child-bearing potential 1 must have a negative pregnancy test performed before the inclusion in the study V e r s i o n 6 . 0 - P a g . 10 \| 32 * Willingness to participate in the study (signed informed consent) IN PARTICIPANTS WITH Type 2 Diabetes * Clinical diagnosis of T2DM for at least 1 year * Hemoglobin A1c (HbA1c) value of \< 9.5% * Patients treated only with metformin and/or repaglinide * A diagnosis of Diabetic Nephropathy at renal biopsy made not more than 6 months before the screening visit (only for the subgroup of patients candidated to the second kidney biopsy) * Proteinuria \> 1g/24h (only for the subgroup of patients candidated to the second kidney biopsy) * Hemoglobin A1c (HbA1c) value of \> 6.5% (only for patients candidated to the second kidney biopsy) In PARTICIPANTS Without Type 2 Diabetes * diagnosis of hypertension for at least 5 years …